Apexigen

View All

Delveinsight
Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup

Sarepta builds in gene therapy with $30M Lacerta deal Sarepta has dampen its enthusiasm for an ongoing gene therapy candidate. Sarepta has made a tie-up with lacerta that will add 3 more programs to 8 already existing and are ready to expand its focus beyond muscular dystrophy. Sarepta has committed to pay Lacerta ...

Find More

severe combined Immunodeficiency
Immune Checkpoint Activators (ICA): Dynamic Therapeutic Targets

Immune checkpoints are the regulators of immune activation. They play a key role in maintaining immune homeostasis and preventing autoimmunity. Immune checkpoint activators are small molecules responsible for maintenance, modulation, and regulation of immune responses. Its significance in immune-therapeutics is back...

Find More